TRIAL HOLDINGS INC. |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2,818 JPY | +0.07% |
|
+2.81% | 0.00% |
| May. 06 | Calliditas Therapeutics' Potential Head and Neck Cancer Treatment Meets Secondary Endpoints | MT |
| May. 06 | UK Tribunal Greenlights GBP790 Million Lawsuit vs Prysmian, Nexans, NKT | MT |
Valuation
| Fiscal Period: June | 2024 | 2025 | 2026 |
|---|---|---|---|
| Capitalization 1 | 333,751 | - | - |
| Enterprise Value (EV) 1 | 308,454 | 309,778 | 315,891 |
| P/E ratio | 31.5 x | 25.3 x | 22.1 x |
| Yield | 0.37% | 0.64% | 0.71% |
| Capitalization / Revenue | 0.47 x | 0.42 x | 0.38 x |
| EV / Revenue | 0.43 x | 0.39 x | 0.36 x |
| EV / EBITDA | 9.71 x | 8.24 x | 7.32 x |
| EV / FCF | - | - | - |
| FCF Yield | - | - | - |
| Price to Book | 3.15 x | 2.85 x | 2.57 x |
| Nbr of stocks (in thousands) | 118,520 | - | - |
| Reference price 2 | 2,816 | 2,816 | 2,816 |
| Announcement Date | - | - | - |
1JPY in Million2JPY
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: Juni | 2024 | 2025 | 2026 |
|---|---|---|---|
| Net sales 1 | 714,677 | 790,116 | 881,895 |
| EBITDA 1 | 31,767 | 37,599 | 43,169 |
| EBIT 1 | 19,336 | 22,979 | 26,342 |
| Operating Margin | 2.71% | 2.91% | 2.99% |
| Earnings before Tax (EBT) | - | - | - |
| Net income 1 | 10,885 | 13,589 | 15,559 |
| Net margin | 1.52% | 1.72% | 1.76% |
| EPS 2 | 89.26 | 111.4 | 127.6 |
| Free Cash Flow | - | - | - |
| FCF margin | - | - | - |
| FCF Conversion (EBITDA) | - | - | - |
| FCF Conversion (Net income) | - | - | - |
| Dividend per Share 2 | 10.37 | 18.00 | 20.00 |
| Announcement Date | - | - | - |
1JPY in Million2JPY
Estimates
Balance Sheet Analysis
| Fiscal Period: Juni | 2024 | 2025 | 2026 |
|---|---|---|---|
| Net Debt 1 | - | - | - |
| Net Cash position 1 | 25,297 | 23,972 | 17,860 |
| Leverage (Debt/EBITDA) | - | - | - |
| Free Cash Flow | - | - | - |
| ROE (net income / shareholders' equity) | 16.5% | 12.5% | 12.9% |
| ROA (Net income/ Total Assets) | - | - | - |
| Assets 1 | - | - | - |
| Book Value Per Share 2 | 893.0 | 987.0 | 1,094 |
| Cash Flow per Share | - | - | - |
| Capex | - | - | - |
| Capex / Sales | - | - | - |
| Announcement Date | - | - | - |
1JPY in Million2JPY
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
1
Last Close Price
2,816
JPY
Average target price
3,200
JPY
Spread / Average Target
+13.64%
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| 0.00% | 2.15B | |
| +15.65% | 342B | |
| +12.06% | 74.21B | |
| -8.44% | 67.79B | |
| +1.15% | 30.73B | |
| +25.53% | 24.07B | |
| +9.45% | 14.57B | |
| +20.37% | 9.4B | |
| -4.07% | 6.66B | |
| +3.57% | 4.87B |
- Stock Market
- Equities
- 141A Stock
- Financials Trial Holdings Inc.